ERBB2 and neoplasm: 70.3% (n = 546) of the cases had a luminal tumour (ER+ and/or PR+ with HER2 negative), 18.5% (n = 144) had a HER2+ tumour and the remaining 11.2% (n = 87) had a TN (ER−, PR− and HER2) tumour (Table S2).